Bausch + Lomb CEO on turnaround, AI and TrumpRx Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M T W Thu F 13 November, 2025

Our latest survey captured the bleakest biotech outlook in a decade — but is recent momentum real or a mirage? Join us to hear what CEOs are saying about the industry’s direction. Sign up now.

presented by Da­ta Built for Dis­cov­ery: Ad­vanc­ing Pre­ci­sion Med­i­cine Through In­ten­tion­al De­sign

news Q&A: Brent Saunders on pushing Bausch out of neutral, scrutinizing new hires and why TrumpRx matters Korro Bio abandons lead genetic disease drug candidate after disappointing data FDA unveils new path to speed personalized therapies, inspired by Baby KJ Zealand pauses development of GLP-1/GLP-2 obesity candidate Novartis says Phase 3 data prove new antimalarial could address resistance

Nov 12 2:30pm ET From JP Morgan to the next wave: What's driving biotech in 2026 sponsored by Precision AQ Nov 13 11:00am ET Driving down the cost: Optimising CGT with the right CDMO partner sponsored by OXB Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine

Clinical trials are slower and costlier than ever — yet the pressure to move fast has never been higher. Join Endpoints News for a conversation on what’s shifting, what’s working, and where the industry goes next. Sign up today.

endpoints pharma Chinese biotechs are shedding their fast-follower reputations as innovation surges Pazdur vs. Prasad: Can the CDER-CBER dynamic change under new leadership? WuXi AppTec plants 'flag down' in Europe with new Munich headquarters  Lilly drops CVS as drug benefits manager in favor of upstart Rightway — report

in case you missed it 1. After a frenzied year of dealmaking, here’s how the PD-(L)1xVEGF bispecific race is looking so far 2. Alkermes' stock drops as second Phase 2 narcolepsy trial hits statistical significance — but just barely 3. Immatics shares early bispecific data as it seeks to make its name beyond cell therapy 4. News Briefing Metagenomi's CEO exit, workforce cuts; Cogent's $475M+ raise 5. Exclusive: Beacon Biosignals raises $86M to build and mine brain data trove